ESMO: Radiation Plus Hormone Therapy Is Prostate Cancer Plus

October 6, 2006

ISTANBUL, Turkey -- Progression-free survival is prolonged by 10% in men with locally advanced prostate cancer who receive both radiation and hormone therapy, according to a large meta-analysis.

ISTANBUL, Turkey, Oct. 6 -- Progression-free survival is prolonged by 10% in men with locally-advanced prostate cancer who receive both radiation and hormone therapy, Italian researchers reported here.

In a meta-analysis of 4,373 patients who had participated in seven randomized controlled phase III trials, there was a relative risk of relapse of 0.74 (95% confidence interval, 0.70, 0.78, P